311 related articles for article (PubMed ID: 11695563)
1. Tg.AC genetically altered mouse: assay working group overview of available data.
Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
Toxicol Pathol; 2001; 29 Suppl():60-80. PubMed ID: 11695563
[TBL] [Abstract][Full Text] [Related]
2. The Tg.AC (v-Ha-ras) transgenic mouse: nature of the model.
Tennant RW; Stasiewicz S; Eastin WC; Mennear JH; Spalding JW
Toxicol Pathol; 2001; 29 Suppl():51-9. PubMed ID: 11695562
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Tg.AC transgenic mouse assay for testing the human carcinogenic potential of pharmaceuticals--practical pointers, mechanistic clues, and new questions.
Sistare FD; Thompson KL; Honchel R; DeGeorge J
Int J Toxicol; 2002; 21(1):65-79. PubMed ID: 11936901
[TBL] [Abstract][Full Text] [Related]
4. Neonatal mouse model: review of methods and results.
McClain RM; Keller D; Casciano D; Fu P; MacDonald J; Popp J; Sagartz J
Toxicol Pathol; 2001; 29 Suppl():128-37. PubMed ID: 11695548
[TBL] [Abstract][Full Text] [Related]
5. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent components.
Thompson KL; Rosenzweig BA; Weaver JL; Zhang J; Lin KK; Sistare FD
Toxicol Sci; 2003 Aug; 74(2):271-8. PubMed ID: 12773758
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after dermal application--part II.
Torrey CE; Wall HG; Campbell JA; Kwanyuen P; Hoivik DJ; Miller RT; Allen JS; Jayo MJ; Selinger K; Santostefano MJ
Int J Toxicol; 2005; 24(5):327-39. PubMed ID: 16257852
[TBL] [Abstract][Full Text] [Related]
8. Oral and dermal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces cutaneous papillomas and squamous cell carcinomas in female hemizygous Tg.AC transgenic mice.
Wyde ME; Braen AP; Hejtmancik M; Johnson JD; Toft JD; Blake JC; Cooper SD; Mahler J; Vallant M; Bucher JR; Walker NJ
Toxicol Sci; 2004 Nov; 82(1):34-45. PubMed ID: 15282402
[TBL] [Abstract][Full Text] [Related]
9. Development of a transgenic mouse model for carcinogenesis bioassays: evaluation of chemically induced skin tumors in Tg.AC mice.
Spalding JW; French JE; Tice RR; Furedi-Machacek M; Haseman JK; Tennant RW
Toxicol Sci; 1999 Jun; 49(2):241-54. PubMed ID: 10416269
[TBL] [Abstract][Full Text] [Related]
10. Statistical analysis of skin tumor data from Tg.AC mouse bioassays.
Dunson DB; Haseman JK; van Birgelen AP; Stasiewicz S; Tennant RW
Toxicol Sci; 2000 Jun; 55(2):293-302. PubMed ID: 10828260
[TBL] [Abstract][Full Text] [Related]
11. Oxymetholone: II. Evaluation in the Tg-AC transgenic mouse model for detection of carcinogens.
Holden HE; Stoll RE; Blanchard KT
Toxicol Pathol; 1999; 27(5):507-12. PubMed ID: 10528629
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. I. Evidence for a confounding nonresponder phenotype.
Weaver JL; Contrera JF; Rosenzweig BA; Thompson KL; Faustino PJ; Strong JM; Ellison CD; Anderson LW; Prasanna HR; Long-Bradley PE; Lin KK; Zhang J; Sistare FD
Toxicol Pathol; 1998; 26(4):532-40. PubMed ID: 9715512
[TBL] [Abstract][Full Text] [Related]
13. CB6F1-rasH2 mouse: overview of available data.
Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of SEPA 0009-induced tumorigenesis in v-rasHa transgenic Tg.AC mice.
Fuhrman J; Shafer L; Repertinger S; Chan T; Hansen LA
Toxicol Pathol; 2005; 33(6):623-30. PubMed ID: 16176921
[TBL] [Abstract][Full Text] [Related]
15. Hemizygous Tg.AC transgenic mouse as a potential alternative to the two-year mouse carcinogenicity bioassay: evaluation of husbandry and housing factors.
Holden HE; Stoll RE; Spalding JW; Tennant RW
J Appl Toxicol; 1998; 18(1):19-24. PubMed ID: 9526830
[TBL] [Abstract][Full Text] [Related]
16. The Tg.AC mouse model passes test by failing to respond.
Cannon RE
Toxicol Sci; 2003 Aug; 74(2):233-4. PubMed ID: 12892072
[No Abstract] [Full Text] [Related]
17. Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.
Lina BA; Woutersen RA; Bruijntjes JP; van Benthem J; van den Berg JA; Monbaliu J; Thoolen BJ; Beems RB; van Kreijl CF
Toxicol Pathol; 2004; 32(2):192-201. PubMed ID: 15200157
[TBL] [Abstract][Full Text] [Related]
18. Xpa and Xpa/p53+/- knockout mice: overview of available data.
van Kreijl CF; McAnulty PA; Beems RB; Vynckier A; van Steeg H; Fransson-Steen R; Alden CL; Forster R; van der Laan JW; Vandenberghe J
Toxicol Pathol; 2001; 29 Suppl():117-27. PubMed ID: 11695547
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness.
Thompson KL; Rosenzweig BA; Sistare FD
Toxicol Pathol; 1998; 26(4):548-55. PubMed ID: 9715514
[TBL] [Abstract][Full Text] [Related]
20. P53+/- hemizygous knockout mouse: overview of available data.
Storer RD; French JE; Haseman J; Hajian G; LeGrand EK; Long GG; Mixson LA; Ochoa R; Sagartz JE; Soper KA
Toxicol Pathol; 2001; 29 Suppl():30-50. PubMed ID: 11695560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
